Kapstone Financial Advisors LLC Sells 290 Shares of Johnson & Johnson (NYSE:JNJ)

Kapstone Financial Advisors LLC cut its position in shares of Johnson & Johnson (NYSE:JNJFree Report) by 3.4% in the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 8,246 shares of the company’s stock after selling 290 shares during the quarter. Johnson & Johnson accounts for about 1.1% of Kapstone Financial Advisors LLC’s portfolio, making the stock its 21st biggest holding. Kapstone Financial Advisors LLC’s holdings in Johnson & Johnson were worth $1,284,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. State Street Corp boosted its position in Johnson & Johnson by 1.1% during the second quarter. State Street Corp now owns 141,833,756 shares of the company’s stock valued at $23,476,323,000 after purchasing an additional 1,568,633 shares during the last quarter. Moneta Group Investment Advisors LLC boosted its position in Johnson & Johnson by 90,144.4% during the fourth quarter. Moneta Group Investment Advisors LLC now owns 54,386,720 shares of the company’s stock valued at $9,607,414,000 after purchasing an additional 54,326,454 shares during the last quarter. Geode Capital Management LLC boosted its position in Johnson & Johnson by 2.0% during the second quarter. Geode Capital Management LLC now owns 49,697,798 shares of the company’s stock valued at $8,203,608,000 after purchasing an additional 990,298 shares during the last quarter. Morgan Stanley boosted its position in Johnson & Johnson by 12.0% during the fourth quarter. Morgan Stanley now owns 42,224,521 shares of the company’s stock valued at $7,458,962,000 after purchasing an additional 4,521,062 shares during the last quarter. Finally, Capital International Investors boosted its position in Johnson & Johnson by 62.7% during the second quarter. Capital International Investors now owns 27,825,795 shares of the company’s stock valued at $4,605,627,000 after purchasing an additional 10,724,110 shares during the last quarter. 68.40% of the stock is currently owned by institutional investors.

Johnson & Johnson Trading Up 0.1 %

Shares of JNJ opened at $158.90 on Thursday. The company has a debt-to-equity ratio of 0.37, a quick ratio of 0.96 and a current ratio of 1.21. Johnson & Johnson has a 52-week low of $144.95 and a 52-week high of $175.97. The firm has a market cap of $382.52 billion, a price-to-earnings ratio of 11.51, a PEG ratio of 2.68 and a beta of 0.53. The business’s fifty day moving average is $157.63 and its 200-day moving average is $159.24.

Johnson & Johnson (NYSE:JNJGet Free Report) last released its quarterly earnings data on Tuesday, January 23rd. The company reported $2.29 earnings per share for the quarter, beating the consensus estimate of $2.28 by $0.01. Johnson & Johnson had a return on equity of 36.75% and a net margin of 37.79%. The company had revenue of $21.40 billion for the quarter, compared to the consensus estimate of $21.02 billion. During the same quarter last year, the business posted $2.35 EPS. Johnson & Johnson’s revenue for the quarter was down 9.7% on a year-over-year basis. Equities analysts anticipate that Johnson & Johnson will post 10.66 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 5th. Investors of record on Tuesday, February 20th will be issued a dividend of $1.19 per share. This represents a $4.76 annualized dividend and a dividend yield of 3.00%. The ex-dividend date of this dividend is Friday, February 16th. Johnson & Johnson’s dividend payout ratio (DPR) is 34.47%.

Analyst Ratings Changes

Several research analysts recently commented on the company. UBS Group raised Johnson & Johnson from a “neutral” rating to a “buy” rating and increased their price target for the company from $167.00 to $180.00 in a research report on Friday, December 1st. Raymond James raised their price objective on Johnson & Johnson from $172.00 to $175.00 and gave the company an “outperform” rating in a research report on Wednesday, January 3rd. TheStreet cut Johnson & Johnson from a “b” rating to a “c+” rating in a research report on Friday, November 17th. Morgan Stanley cut their price objective on Johnson & Johnson from $170.00 to $169.00 and set an “equal weight” rating for the company in a research report on Wednesday, January 24th. Finally, Cantor Fitzgerald reissued an “overweight” rating and set a $215.00 price target on shares of Johnson & Johnson in a report on Tuesday, January 23rd. Eight equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $167.87.

Check Out Our Latest Research Report on JNJ

About Johnson & Johnson

(Free Report)

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.

Featured Stories

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.